FDAsafety guidance65% confidence
FDA AP — ALENDRONATE SODIUM (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Aurobindo Pharma.
Regulatory Analysis
Application ANDA090124. Sponsor: AUROBINDO PHARMA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ALENDRONATE SODIUM.
Supporting Context
- Therapeutic area
- Neurology · Antiepileptic
- Sub-indication
- General
Related signal: Aurobindo Pharma's Divalproex Sodium ANDA202419 Receives AP Status